The BSC/CA INBC's are indicated for use in patients with the following conditions *Refractory power failure. *Cardiogenic shock. *Unstable refractory angina. *Impending or extending myocardial infarction (MI). *Hemodynamically significant mechanical complications secondary to acute MI: *Ventricular septal defect. *Mitral valve regurgitation. *Papillary muscle rupture. *Cardiac support for high risk general surgical and coronary angiography/ angioplasty patients. *Septic shock. The intended use of the 40 cc Grande. " remains identicalto that of the currently marketed IABC's. All of the devices are intended to provide temporary circulatory support of the left ventricle through controlled mechanical displacement of a volume of blood in the aorta. The mechanical action of the IAB catheter therapy lowers the cardiac workload by two means : Systolic unloading, as noted by a reduction in the patient's systolic pressure, which provides reduced myocardial oxygen consumption (MVO,). Diastolic augmentation which provides an increase in the mean aortic pressure and leads to an improvement in systemic and coronary arterial perfusion. Balloon pump therapy is achieved by inserting and intra-aortic balloon catheter into the descending thoracic aorta via the common femoral arterv. Balloon inflation is timed to occur during diastole, beginning with the aortic valve closure. The balloon remains inflated until the onset of left ventricular ejection or systole, then rapidly deflates, reducing the aortic pressure, which in turn reduces the afterload.

Device Description

The proposed 40 cc Grande™ consists of a polyurethane blend symmetrical balloon at the distal end of a polyurethane-covered nylon shaft. The balloon is coated with a thin layer of silicone fluid. A polvurethane central lumen runs throughout the length of the catheter and terminates at the distal tip. This central lumen may be used to pass the device over a guidewire. The balloon is supplied prewrapped for insertion and supplied with a 0.025 inch extra stiff quidewire and 10 F introducer.

AI/ML Overview

The provided text describes the non-clinical performance testing of the 40 cc Grande™ Intra-Aortic Balloon Catheter. There are no clinical studies or human reader studies reported for this device. Therefore, information regarding MRMC studies, human reader improvement with AI, or standalone algorithm performance cannot be provided.

Here's an analysis of the acceptance criteria and study findings based on the provided document:

1. Table of Acceptance Criteria and Reported Device Performance

Test	Acceptance Criteria	Reported Device Performance	Substantially Equivalent To Predicate Device
Initial Performance Testing (Unwrapping & Integrity)	Device unwraps according to Directions for Use & QA final acceptance criteria. Maintains integrity after insertion/removal (twice) & re-insertion.	All proposed 40 cc Grande™ IABs opened (unwrapped) as per DFU and QA final acceptance criteria. Demonstrated integrity post insertion/removal.	Not explicitly stated as "substantially equivalent" for this test, but implies satisfactory performance against defined criteria.
Sheathed Insertion Test (Force)	Not explicitly stated with a numerical criterion, but implied to be comparable to predicate.	34.8 oz force required.	Substantially equivalent to predicate Model 940 (30.1 oz).
Sheathless Insertion Test (Tightest Restriction)	Device passes through 0.100 inch restriction 100% of the time. (Note: Dilator size 0.118 inch provided).	0.100 inch (100% of the time).	Substantially equivalent to: - predicate 40 cc Grande NT™ (0.100 inch) - 40 cc Datascope 9.5 F Percor-Stat (0.100 inch) - 40 cc 9 F Kontron/Arrow IAB (> 0.105 inch).
Maximum Pumping Rate Limit Test	≥ 90% of nominal volume inflated/deflated.	175 bpm.	Substantially equivalent to predicate 40 cc Grande NT™ (170 bpm) and greater than Model 940 (140 bpm).
Combined Inflation/Deflation Time	Not explicitly stated with a numerical criterion, but implied to be comparable to predicate.	245 msec.	Compares favorably with predicate Model 940 (275 msec) and 40 cc Grande NT™ (264 msec).
Reliability and Integrity Test	Minimum 3.6 million cycles without failure (dimensional changes, surface wear, leaks).	All 40 cc Grande™ test samples able to cycle reliably. No changes in dimensions, signs of surface wear, or leaks noted after 3.6 million cycles. Pre-reliability maximum pumping rate (175 bpm) nearly identical to post-reliability (176 bpm). Inflation/deflation times comparable post-reliability.	As reliably as the predicate devices (40 cc Grande NT™ and Model 940).
Trackability Test	Catheters and insertion accessories perform without incident (no kinks, problems inserting/removing).	All 40 cc Grande™ and predicate devices tracked their guidewire into place without incident. No catheter kinks, no guidewire kinks, no problems encountered inserting or removing.	Implied to be equivalent to predicate devices.
Transmembrane Pressure and Volume Measurement Test (Volume at 50 mmHg)	40 cc +/- 5%.	41.6 cc.	Substantially equivalent to predicate 40 cc Grande NT™ (41.7 cc).
Transmembrane Pressure and Volume Measurement Test (Pressure at 40 cc displacement)	< 50 mmHg.	Average 21.5 mmHg.	Substantially equivalent to predicate 40 cc Grande NT™ (26.7 mmHg).
Kink Resistance Test	Not explicitly stated with a numerical criterion, but implied to be comparable or better than predicate.	Mean kink radius of 0.51 inch.	Less than predicate Model 940 (0.54 inch). (Indicates better kink resistance).

2. Sample Size Used for the Test Set and Data Provenance

The document does not specify a precise numerical sample size for each test (e.g., "N=10 devices were tested"). Instead, it generally refers to "test samples." For example, "test samples were tested on the BSC/CA 3001 IABP" for initial performance, and "The 40 cc Grande™ test samples were all able to cycle as reliably..." for reliability testing.

Sample Size: Not explicitly stated as a single number for each test. Referred to as "test samples."
Data Provenance: The tests conducted are non-clinical, in-vitro bench tests performed by the manufacturer, Boston Scientific Corporation / Cardiac Assist (BSC/CA). The country of origin for the data is not specified, but it would be from the manufacturer's testing facilities. The data is prospective in the sense that the tests were conducted specifically to support this premarket notification.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

This information is not applicable as the described tests are non-clinical, in-vitro performance tests for a medical device (intra-aortic balloon catheter). There is no "ground truth" in the clinical sense established by human experts for these types of mechanical performance evaluations. The "ground truth" is typically defined by engineering specifications, regulatory standards, and comparative performance against established predicate devices.

4. Adjudication Method for the Test Set

This information is not applicable. Adjudication methods (like 2+1, 3+1) are typically used in clinical studies or expert consensus reviews, especially for diagnostic or prognostic assessments, to resolve discrepancies in expert opinions. The tests described are objective, quantitative measurements of device performance, not subjective assessments requiring adjudication.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, If So, What Was the Effect Size of How Much Human Readers Improve with AI vs Without AI Assistance

No, a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not conducted. This document describes the non-clinical performance of a medical device, not a diagnostic or AI-assisted interpretation tool for human readers.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

This information is not applicable. The device being described is a physical medical device (an intra-aortic balloon catheter), not a software algorithm or AI.

7. The Type of Ground Truth Used

The "ground truth" for these non-clinical tests is based on:

Engineering Specifications and Design Requirements: The device is designed to meet specific performance parameters (e.g., volume, pressure, maximum pumping rate).
Predicate Device Performance: The primary "ground truth" or benchmark for many tests is the performance of legally marketed predicate devices (40 cc Grande NT™ and Model 940). The goal is to demonstrate "substantial equivalence" to these devices.
Internal QA Final Acceptance Criteria: For some tests, such as initial unwrapping, the device's performance is measured against the manufacturer's internal Quality Assurance (QA) final acceptance criteria.
Regulatory Standards: Implied adherence to general regulatory standards for medical device safety and effectiveness.

8. The Sample Size for the Training Set

This information is not applicable. There is no "training set" as this is not an AI/machine learning study. The data relates to the physical testing of a medical device.

9. How the Ground Truth for the Training Set Was Established

This information is not applicable for the same reasons as point 8.

Summary

{0}------------------------------------------------

897424

1998

Image /page/0/Figure/1 description: The image shows a rectangular box with the text "510(k) SUMMARY" inside. The text is in bold and capital letters. Below the box, there is the text "FEB | O", which appears to be a date.

Pursuant to Section 513(i)(3)(A) of the Federal Food, Drug and Cosmetic Act, within this Premarket Notification either an "... adequate summary of any information respecting safety and effectiveness or state that such information will be made available upon request of any person." BSC/CA chooses to submit a summary of information regarding safety and effectiveness.

GENERAL INFORMATION A.

Submitter's Name: Boston Scientific Corporation One Boston Scientific Place Natick, MA 01760-1537

Contact Person: Leo Basta Director, Requlatory Affairs and Clinical Research

Preparation Date: 11 November 1997

B. DEVICE INFORMATION

Intra-Aortic Balloon Catheter Device Generic Name:

40 cc Grande™ Device Trade Name:

Percutaneous Intra-Aortic Balloon Catheter Classification Name:

PREDICATE DEVICE INFORMATION ்.

The following devices are referenced in this premarket notification as predicate devices for the 40 cc Grande™, subject of this submission:

K971673: 40 cc SUMO for use on BSC/CA 3001, Datascope Systems 90 and 97. Kontron KAAT, St. Jude/Aries 700 and Bard H-8000.

K963187: Modified labeling of BSC/CA IAB's.

K954431: Modified Model 940 and Model 930 for use on BSC/CA 3001, Datascope Systems 90 and 97, Kontron KAAT, St. Jude/Aries 700 and Bard H-8000.

K952221: 30 cc and 40 cc Sensation™, Model 940 and Model 930 for use on Bard H-8000.

K940298: Model 940 for use on BSC/CA 3001. Datascope Systems 90 and 97, Kontron KAAT and St. Jude/Aries 700.

{1}------------------------------------------------

FDA has concurred with the substantial equivalence determination of the All of these devices are above referenced premarket notifications. currently legally marketed.

PROPOSED DEVICE INFORMATION D.

This premarket notification proposes the following changes to the current legally marketed 40 cc Grande NTTM:

The proposed 40 cc Grande™ has a polyurethane central lumen. The polvurethane central lumen design is similar to that of the predicate Model 940 with a smaller ID and OD.

DEVICE DESCRIPTION പ്

The proposed 40 cc Grande™ consists of a polyurethane blend symmetrical balloon at the distal end of a polyurethane-covered nylon The balloon is coated with a thin layer of silicone fluid. shaft. A polvurethane central lumen runs throughout the length of the catheter and terminates at the distal tip. This central lumen may be used to pass the device over a guidewire. The balloon is supplied prewrapped for insertion and supplied with a 0.025 inch extra stiff quidewire and 10 F introducer.

F. INDICATIONS FOR USE

The indications for use for the 40 cc Grande™ is identical to that of the currently marketed predicate devices. The indications are as follows:

· Refractory power failure.
· Cardiogenic shock.
· Unstable refractory angina.
· Impending or extending myocardial infarction (MI).

Hemodynamically significant mechanical complications secondary to acute MI:

· Ventricular septal defect.
· Mitral valve regurgitation.
· Papillary muscle rupture.
· Angiography/Angioplasty patients.
· Septal shock.

C. TECHNOLOGICAL CHARACTERISTICS

The 40 cc Grande™ is Identical to the predicate 40 cc Grande NTTM except for the central lumen which is made of polyurethane (same as predicate Model 940 with smaller ID and OD). Test data and information demonstrates that the use of the 40 cc Grande™ is substantially equivalent to the performance of the predicate devices on the BSC/CA 3001, Datascope Systems 90 and 97, St. Jude/Aries 700, Kontron KAAT and Bard H-8000 IABP's.

{2}------------------------------------------------

H. NONCLINICAL TESTS

1. Initial Performance Testing:

To demonstrate the unwrapping and integrity of the 40 cc Grande™ post insertion and removal, test samples were tested on the BSC/CA 3001 IABP. All the proposed 40 cc Grande™ IAB's opened (unwrapped) per the Directions for Use and QA final acceptance criteria. Demonstration that the proposed 40 cc Grande™ can be inserted and removed from it's introducer twice, inserted into another introducer and passed the unwrapping test demonstrates the integrity of the device post insertion and removal.

2. Sheathed Insertion Test:

The force required to insert the 40 cc Grande™ through it's introducer, over it's guidewire at 34.8 oz was demonstrated to be substantially equivalent to the force required to insert the predicate Model 940 at 30.1 OZ.

1. Sheathless Insertion Test:
  The tightest restriction that the 40 cc Grande™ can pass through 100% of the time is 0.100 inch which is substantially equivalent to the predicate 40 cc Grande NT™ at 0.100 inch, the 40 cc Datascope 9.5 F Percor-Stat at 0.100 inch and the 40 cc 9 F Kontron/Arrow IAB at > 0.105 inch. This restriction is well below the 0.118 inch dilator size provided for use with the sheathless introduction technique.
1. Maximum Pumping Rate Limit Test:
  The maximum pumping rate limit, defined as the maximum pumping rate at which the balloon is able to inflate and deflate fully (greater than or equal to 90% of it's nominal volume), was measured for the 40 cc Grande™ on the BSC/CA 3001 IABP. The maximum pumping rate limit was 175 bpm which is substantially equivalent to the predicate 40 cc Grande NTM at 170 bpm and greater than the Model 940 at 140 bpm.

The proposed 40 cc Grande™ combined inflation/deflation time of 245 msec compares favorably with the combined inflation/deflation times of the predicate Model 940 at 275 msec and 40 cc Grande NTTM at 264 msec.

1. Reliability and Integrity Test:
  The reliability of the 40 cc Grande™ was compared to that of the predicate 40 cc Grande NTTM and Model 940 by pumping test samples for a minimum of 3.6 million cycles. The 40 cc Grande™ test samples were all able to cycle as reliably as the predicate devices.

Dimensional inspection, visual inspection for signs of surface wear, and leak testing were performed following reliability testing. No changes in dimensions, signs of surface wear or leaks were noted.

{3}------------------------------------------------

Following reliability testing, dimensional and visual inspections and leak testing, the 40 cc Grande™ test samples were subjected to a maximum pumping rate limit test on the BSC/CA 3001. The maximum pumping rate limit post-reliability was 176 bpm which compares well with the prereliability value of 175 bpm. Inflate and deflate times were also found comparable post-reliability versus pre-reliability testing.

6. Trackability Test:

40 cc Grande™ test samples were inserted over their guidewire, into position, and withdrawn as a set to demonstrate that the catheters can perform with their insertion accessories. All the 40 cc Grande™ as well as the predicate devices were able to track their guidewire into place without There were no catheter kinks, no guidewire kinks, nor any incident. problems encountered inserting or removing the catheters through their introducer.

7. Transmembrane Pressure and Volume Measurement Test:

The volume of the 40 cc Grande™ at a transmembrane pressure of 50 mmHq was found to be 41.6 cc which meets the acceptance criteria of 40 cc +/- 5% and is substantially equivalent to the predicate 40 cc Grande NT™ at 41.7 cc.

At a 40 cc displacement, the 40 cc Grande™ transmembrane pressure on average will be 21.5 mmHg which meets the acceptance criteria of < 50 mmHg and is substantially equivalent to the predicate 40 cc Grande NTTM at 26.7 mmHg.

Kink Resistance Test:

40 cc Grande™ test samples were manufactured, sterilized, aged to their intended shelf life of 2 years and tested for their ability to bend around the smallest radius without failure. The proposed 40 cc Grande™ with a mean kink radius of 0.51 inch was found to be less than the predicate Model 940 at 0.54 inch.

CUNICAL TESTS .

No clinical testing was was was and performed by Boston Scientific Corporation/Cardiac Assist in support of this premarket notification.

. ل PACKAGING AND STERILIZATION

There are no changes to the packaging and sterilization of the 40 cc Grande™ as compared to the predicate devices. The catheters are placed in a plastic tray and sealed into Tyvek/Mylar pouches and sterilized using 100% Ethylene Oxide gas. Ethylene oxide gas residuals and bacterial endotoxin levels are monitored for compliance with maximum release limits.

{4}------------------------------------------------

POTENTIAL COMPLICATIONS K.

Potential complications associated with the use of intra-aortic balloon catheters, in general, appear in the device's Directions for Use and are reproduced below.

· Leg ischemia.
· Femoral, aortic or illiac dissection.
· Arterial injury.
Renal artery occlusion.
· Arterial rupture.
· Arterial perforation.
· Hypotension.
Distal embolization. .
· Death.
Vascular thrombosis. .
· Short-term hemodynamic deterioration.
· Hemorrhage.
· Arteriovenous fistula formation.

CONCLUSIONS لــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ

Based on the functional and performance data and information submitted in this premarket notification, Boston Scientific Corporation/Cardiac Assist believes that the 40 cc Grande™ is substantially equivalent to the predicate devices, the 40 cc Grande NTTM and Model 940, for use on the BSC/CA 3001, Datascope Systems 90 and 97, St. Jude/Aries 700, Kontron KAAT and Bard H-8000 IABP's.

{5}------------------------------------------------

Image /page/5/Picture/2 description: The image is a black and white seal for the Department of Health & Human Services - USA. The seal is circular with text around the perimeter. The central image is a stylized design of an eagle.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

FEB 10 1998

Mr.• Leo Basta Director, Regulatory Affairs and Clinical Research Boston Scientific Corporation One Boston Scientific Place Natick, MA 01760-1537

Re : K974247 Cardiac Assist 40 CC Grande™ Intra-Aortic Balloon Catheter Regulatory Class: III (three) Product Code: 74 DSP Dated: November 11, 1997 Received: November 12, 1997

Dear Mr. Basta:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any. . . obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

{6}------------------------------------------------

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4648. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".

Sincerely yours,

Thomas J. Callahan

Thomas J. CaMahan, Ph.D. Director Division of Cardiovascular, Respiratory, and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{7}------------------------------------------------

Control 870, 3535 - DSP II - Intraactic Dalloon and

510(k) Number (if known):K974247	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
--------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Device Name: Bosson SCIENTIEK 9 FR 9 8 CR SOLL GATTLE THE INTER ADETIC BALLOON CATHETER

Indications For Use:

The BSC/CA INBC's are indicated for use in patients with the following conditions *Refractory power failure. *Cardiogenic shock.

*Unstable refractory angina.

*Hemodynamically significant mechanical complications secondary to acute MI: *Ventricular septal defect.
- *Mitral valve regurgitation.
- *Papillary muscle rupture.

*Cardiac support for high risk general surgical and coronary angiography/ angioplasty patients.

*Septic shock.

The intended use of the 40 cc Grande. " remains identicalto that of the currently marketed IABC's. All of the devices are intended to provide temporary circulatory support of the left ventricle through controlled mechanical displacement of a volume of blood in the aorta.

The mechanical action of the IAB catheter therapy lowers the cardiac workload by two means :

Systolic unloading, as noted by a reduction in the patient's systolic 1.
pressure, which provides reduced myocardial oxygen consumption (MVO,). . .
Diastolic augmentation which provides an increase in the mean 2. aortic pressure and leads to an improvement in systemic and coronary arterial perfusion.

Balloon pump therapy is achieved by inserting and intra-aortic balloon catheter into the descending thoracic aorta via the common femoral Balloon inflation is timed to occur during diastole, beginning arterv. with the aortic valve closure. The balloon remains inflated until the onset of left ventricular ejection or systole, then rapidly deflates, reducing the aortic pressure, which in turn reduces the afterload.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Bita Lauseise

(Division Sign-Off) Division of Cardiovascular, Respiratory, and Neurological Devices

510(k) Number_k974247

Prescription Use (Per 21 CFR 801, 109)

Over-The-Counter Use

Regulation Number and Section

§ 870.3535 Intra-aortic balloon and control system.

(a)
Identification. An intra-aortic balloon and control system is a prescription device that consists of an inflatable balloon, which is placed in the aorta to improve cardiovascular functioning during certain life-threatening emergencies, and a control system for regulating the inflation and deflation of the balloon. The control system, which monitors and is synchronized with the electrocardiogram, provides a means for setting the inflation and deflation of the balloon with the cardiac cycle.(b)
Classification. (1) Class II (special controls) when the device is indicated for acute coronary syndrome, cardiac and non-cardiac surgery, or complications of heart failure. The special controls for this device are:(i) Appropriate analysis and non-clinical testing must be conducted to validate electromagnetic compatibility and electrical safety of the device;
(ii) Software verification, validation, and hazard analysis must be performed;
(iii) The device must be demonstrated to be biocompatible;
(iv) Sterility and shelf-life testing must demonstrate the sterility of patient-contacting components and the shelf life of these components;
(v) Non-clinical performance evaluation of the device must demonstrate mechanical integrity, durability, and reliability to support its intended purpose; and
(vi) Labeling must include a detailed summary of the device- and procedure-related complications pertinent to use of the device.
(2) Class III (premarket approval) when the device is indicated for septic shock and pulsatile flow generation.
(c)
Date premarket approval application (PMA) or notice of completion of product development protocol (PDP) is required. A PMA or notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before March 31, 2014, for any intra-aortic balloon and control system indicated for septic shock or pulsatile flow generation that was in commercial distribution before May 28, 1976, or that has, on or before March 31, 2014, been found to be substantially equivalent to any intra-aortic balloon and control system indicated for septic shock or pulsatile flow generation that was in commercial distribution before May 28, 1976. Any other intra-aortic balloon and control system indicated for septic shock or pulsatile flow generation shall have an approved PMA or declared completed PDP in effect before being placed in commercial distribution.